Enhancing Oncology Model (EOM)

Analysis updated November 9, 2026

Strategic questions for your team

Given that EOM requires practices to accept **downside risk** on total Medicare spending across six-month oncology episodes — with repayment obligations to CMS when spending exceeds defined thresholds — does our organization have sufficient capital reserves, stop-loss arrangements, or reinsurance capacity to absorb potential repayment scenarios, and have we stress-tested our exposure across our current patient volume in all seven covered cancer types (high-risk breast, lung, chronic leukemia, small intestine/colorectal, lymphoma, multiple myeloma, high-risk prostate)?
Can we accurately project whether our historical total cost of care for six-month chemotherapy episodes across EOM's seven cancer types falls favorably against CMS's cancer type-specific, risk-adjusted benchmarks — and do we have sufficient claims analytics capability to model our Performance-Based Payment (PBP) position before committing to participation, particularly given that EOM uses cancer type-specific benchmarking rather than the blended approach used in the predecessor Oncology Care Model (OCM)?
Do we have the operational infrastructure to fulfill all eight required Participant Redesign Activities (PRAs) — specifically 24/7 clinician access with EHR availability, a functioning patient navigation program, systematic electronic patient-reported outcomes (ePRO) collection and monitoring, and structured screening for health-related social needs (HRSNs) — and if not, what is the realistic implementation cost and timeline relative to the $110/beneficiary/month MEOS payment ($140/month for dually eligible individuals) that would offset those investments?
Are we currently operating on certified EHR technology capable of supporting ePRO collection, HRSN screening workflows, comprehensive care plan documentation, and the continuous quality improvement data reporting CMS requires — and what is the gap-closure cost if our current systems do not meet these requirements, given that EHR certification is a non-negotiable PRA obligation?
As a Cohort 1 or Cohort 2 participant prospect — recognizing that Cohort 1 began July 1, 2023 (seven-year term through June 30, 2030) and Cohort 2 began July 1, 2025 (five-year term through June 30, 2030) — which cohort reflects our readiness timeline, and have we assessed whether the shorter Cohort 2 runway reduces our opportunity to achieve meaningful Performance-Based Payments given the ramp-up time typically required to bend the cost curve in complex oncology populations?
Beginning in Performance Period 6, a new **Substance Access Beneficiary Engagement Incentive (BEI)** becomes available — have we reviewed the EOM Participant Resources and Substance Access BEI FAQs to determine whether our patient population and care delivery capabilities position us to capture this incremental incentive, and does this new feature materially improve our overall financial case for participation?
Given that MIPS payment adjustment factors explicitly **do not apply** to MEOS payments under the Federal Register Notice CMS has published, how does EOM participation affect our physicians' overall MIPS performance and payment trajectory — and does the MIPS exception for MEOS payments represent a net financial benefit or complication relative to our current MIPS scoring and bonus/penalty position?
With only **23 physician group practices and 1 commercial payer (BlueCross BlueShield of South Carolina)** currently participating in EOM across more than 300 sites of care, what does the limited participation signal about market-level adoption risk — and does entering EOM now represent a first-mover advantage in our region in terms of payer contracting leverage, oncology referral network development, and value-based care reputation, or does thin participation suggest unresolved financial viability concerns we should investigate before committing?
Have we reviewed the publicly released **First Annual Evaluation Report and first reconciliation performance period cost and quality data** (released August 25, 2025) to benchmark our anticipated performance against current EOM participants, and do those early results — particularly on episode spending, quality metrics, and Performance-Based Payment distributions — indicate that practices with our size, payer mix, and cancer type volume are generating net-positive financial outcomes under the model?

Traps and concerns

Benchmark Volatility Across Multi-Episode Patients
EOM's six-month episode design means patients receiving extended chemotherapy regimens can trigger multiple consecutive episodes, each subject to independently set spending benchmarks derived from historical costs and patient characteristics. Practices face compounding reconciliation risk: a patient whose second or third episode coincides with a high-cost event (e.g., hospitalization, new regimen switch) may push total spend above the repayment threshold for that episode even if the practice performed well in prior periods. With seven cancer types — including multiple myeloma and chronic leukemia, which routinely involve prolonged treatment — practices managing high proportions of such patients can experience unpredictable swings in net performance-based payment (PBP) outcomes across reconciliation periods. The first reconciliation data released August 25, 2025 should be scrutinized for episode-stacking patterns; practices that did not model multi-episode patient volume before enrollment may face material repayment obligations they did not budget for.
MEOS Revenue Misclassified as Profit, Not Infrastructure Subsidy
The $110 per beneficiary per month MEOS payment ($140 for dually eligible individuals) is structurally a care transformation subsidy, not a margin generator. Practices that treat MEOS revenue as operating profit without fully funding the eight required Participant Redesign Activities — 24/7 clinician access, patient navigation, ePRO collection, HRSN screening, certified EHR use, evidence-based treatment guidelines, comprehensive care plans, and data-driven QI — are exposed to two simultaneous risks: compliance deficiency findings during CMS audits and structural underinvestment in the interventions that actually drive spending below benchmark. For a practice with 200 attributed beneficiaries per month, gross MEOS revenue is roughly $264,000 annually ($22,000/month), but standing up genuine 24/7 clinical coverage and patient navigation infrastructure in a community oncology setting can cost $300,000–$500,000+ annually. Practices that model MEOS as net revenue rather than an offset to required infrastructure spend will be underfunded and potentially non-compliant simultaneously.
Downside Risk Exposure Without Payer Alignment Outside Medicare
EOM holds Physician Group Practices financially accountable for total Medicare spending during six-month episodes, including repayment obligations when spending exceeds defined thresholds. However, only one commercial payer — BlueCross BlueShield of South Carolina — participates in EOM alongside the 23 PGPs. Practices operating in markets where commercial insurers do not share EOM's care transformation logic face a structural misalignment: the same patients may be managed under fee-for-service commercial contracts that reward volume, not value, creating conflicting care protocols and eroding the practice-wide behavior change needed to consistently beat Medicare benchmarks. Practices with high commercial payer mix relative to Medicare may find that EOM's downside risk sits on top of a commercial revenue base that actively disincentivizes the frugality EOM requires, particularly for high-cost drug selection decisions affecting both payers.
ePRO and HRSN Compliance Operationalization Failures
EOM mandates collection and monitoring of electronic patient-reported outcomes (ePROs) and systematic screening for health-related social needs (HRSNs) as required Participant Redesign Activities — not optional enhancements. Practices that implement these requirements through paper-based workarounds, poorly integrated vendor platforms, or inconsistent workflows risk two distinct regulatory exposures: (1) CMS compliance reviews could find that ePRO collection is not genuinely 'electronic' or not linked to clinical decision-making as required, triggering participation agreement violations; and (2) incomplete HRSN documentation may affect quality metric scoring, which directly gates access to performance-based payments — practices cannot share in savings unless quality thresholds are met. With more than 300 sites of care across 23 PGPs, multi-site practices face particular operational hazard: a single non-compliant site can create model-wide compliance exposure if the participation agreement is held at the PGP level rather than the site level.
Cohort 1 vs. Cohort 2 Participation Agreement Asymmetry
Beginning with Performance Period 6, EOM operates under structurally different participation agreements: the Third Amended and Restated PA governs Cohort 1 participants while the First Amended and Restated PA governs Cohort 2 participants who entered July 1, 2025. These are not administratively equivalent documents. The new Substance Access Beneficiary Engagement Incentive, introduced at PP6, is incorporated into both agreements but under different contractual frameworks. Practices that have staff or legal counsel reviewing only one agreement version — or that assume Cohort 2 terms mirror Cohort 1 terms — risk misunderstanding their specific financial accountability thresholds, quality reporting obligations, and BEI eligibility rules. Health systems managing both cohorts simultaneously (e.g., acquired a Cohort 1 practice and onboarded a Cohort 2 affiliate) face governance complexity if finance and compliance teams do not maintain parallel tracking of materially different contractual obligations under a shared CMS model name.
MIPS Exemption Scope Misapplied to Non-MEOS Revenue
CMS published a Federal Register Notice confirming that MIPS payment adjustment factors will not apply to MEOS payments in EOM. This exemption is narrowly scoped to MEOS payments only. Practices that interpret this as a blanket MIPS exemption for all EOM-related Medicare billing — or that fail to ensure clinicians not attributed to EOM episodes remain subject to standard MIPS requirements — are exposed to MIPS payment adjustments on their broader Part B revenue base. For large multi-specialty PGPs where oncologists are EOM participants but other specialties bill under the same Tax Identification Number, failure to correctly delineate MIPS-exempt vs. MIPS-subject revenue streams could result in unexpected payment adjustments across the entire group's Medicare fee schedule collections, potentially dwarfing any performance-based payment earned through EOM.
Political and Regulatory Discontinuity Under Trump-Era CMMI Restructuring
EOM is a voluntary model authorized under Section 1115A of the Social Security Act, operating under CMMI leadership now held by Abe Sutton as Deputy Administrator and Director. The Trump administration — including CMS Administrator Dr. Mehmet Oz and HHS Secretary RFK Jr. — has signaled interest in restructuring CMMI's portfolio, with DOGE-adjacent scrutiny of federal program overhead. EOM's small participant base (23 PGPs, 1 payer) relative to its administrative infrastructure creates vulnerability: models with limited scale are statistical outliers in cost-savings demonstration and may be flagged for consolidation or early termination. Cohort 2 participants who entered July 1, 2025 and invested in infrastructure to run through June 30, 2030 face the most acute exposure — a model modification or early wind-down would leave five-year capital and operational commitments stranded, with no guaranteed transition payment or protected reconciliation cycle for investments made in good faith under the original participation agreement terms.